210 related articles for article (PubMed ID: 37473683)
1. Targeted drug conjugate systems for ovarian cancer chemotherapy.
Ogundipe OD; Olajubutu O; Adesina SK
Biomed Pharmacother; 2023 Sep; 165():115151. PubMed ID: 37473683
[TBL] [Abstract][Full Text] [Related]
2. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
du Bois A; Lück HJ; Meerpohl HG
Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
[TBL] [Abstract][Full Text] [Related]
3. Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.
Harter P; Hilpert F; Mahner S; Heitz F; Pfisterer J; du Bois A
Expert Rev Anticancer Ther; 2010 Jan; 10(1):81-8. PubMed ID: 20014888
[TBL] [Abstract][Full Text] [Related]
4. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.
van de Laar R; Zusterzeel PL; Van Gorp T; Buist MR; van Driel WJ; Gaarenstroom KN; Arts HJ; van Huisseling JC; Hermans RH; Pijnenborg JM; Schutter EM; Pelikan HM; Vollebergh JH; Engelen MJ; Inthout J; Kruitwagen RF; Massuger LF
BMC Cancer; 2014 Jan; 14():22. PubMed ID: 24422892
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer.
Wood GE; Ledermann JA
Best Pract Res Clin Obstet Gynaecol; 2022 Jan; 78():64-73. PubMed ID: 34607745
[TBL] [Abstract][Full Text] [Related]
6. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
[TBL] [Abstract][Full Text] [Related]
7. Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review.
Poonawalla IB; Parikh RC; Du XL; VonVille HM; Lairson DR
Pharmacoeconomics; 2015 Nov; 33(11):1155-85. PubMed ID: 26072142
[TBL] [Abstract][Full Text] [Related]
8. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.
Trimbos JB; Parmar M; Vergote I; Guthrie D; Bolis G; Colombo N; Vermorken JB; Torri V; Mangioni C; Pecorelli S; Lissoni A; Swart AM; ;
J Natl Cancer Inst; 2003 Jan; 95(2):105-12. PubMed ID: 12529343
[TBL] [Abstract][Full Text] [Related]
9. Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics.
Modesitt SC; Jazaeri AA
Expert Opin Pharmacother; 2007 Oct; 8(14):2293-305. PubMed ID: 17927484
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of epithelial ovarian cancer].
Langmár Z; Csömör S
Orv Hetil; 2006 Aug; 147(34):1627-32. PubMed ID: 17017677
[TBL] [Abstract][Full Text] [Related]
11. Second-line treatment of first relapse recurrent ovarian cancer.
Chua TC; Liauw W; Robertson G; Morris DL
Aust N Z J Obstet Gynaecol; 2010 Oct; 50(5):465-71. PubMed ID: 21039382
[TBL] [Abstract][Full Text] [Related]
12. Medical treatment of epithelial ovarian cancer.
González-Martín AJ
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1125-43. PubMed ID: 15606338
[TBL] [Abstract][Full Text] [Related]
13. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapeutic treatment options for recurrent epithelial ovarian cancer.
Singh N; Jayraj AS; Sarkar A; Mohan T; Shukla A; Ghatage P
Expert Opin Pharmacother; 2023 Jan; 24(1):49-64. PubMed ID: 35968667
[TBL] [Abstract][Full Text] [Related]
15. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
16. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer.
Colombo N; Guthrie D; Chiari S; Parmar M; Qian W; Swart AM; Torri V; Williams C; Lissoni A; Bonazzi C;
J Natl Cancer Inst; 2003 Jan; 95(2):125-32. PubMed ID: 12529345
[TBL] [Abstract][Full Text] [Related]
17. The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer.
Binder PS; Hashim YM; Cripe J; Buchanan T; Zamorano A; Vangveravong S; Mutch DG; Hawkins WG; Powell MA; Spitzer D
BMC Cancer; 2022 Mar; 22(1):263. PubMed ID: 35279106
[TBL] [Abstract][Full Text] [Related]
18. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
[TBL] [Abstract][Full Text] [Related]
19. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers.
Lim PQ; Han IH; Seow KM; Chen KH
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077477
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment.
Ray-Coquard I; Mirza MR; Pignata S; Walther A; Romero I; du Bois A
Cancer Treat Rev; 2020 Nov; 90():102107. PubMed ID: 33099187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
